News – Page 1038 – Endpoints News

Roivant brings Pfizer vets Azoulay, Gulfo into its C-suite; Aileron CEO Joseph Yanchik is out

8 years ago

Syndax is hit with a setback during the ASCO preview round as lead drug flops in mid-stage study

8 years ago

J&J axes its big BACE program in asymptomatic Alzheimer's patients as the drumbeat of PhIII failures rolls on

8 years ago

Allergan faces fresh woes with Restasis patents as Walgreen, retailers file lawsuit over 'anticompetitive conduct'

8 years ago

Forget RNA drugs. Accent gets $40M to develop small molecules that modify RNA instead

8 years ago

Amgen, Novartis ready to roll as FDA green lights blockbuster campaign for migraine drug — priced at $6,900

8 years ago

Who’s delaying generic competition? FDA publishes a long list of drugmakers they say gamed the system

8 years ago

Why would Cohen reach out to Novartis, but not Roche?; WuXi Biologics blueprints big R&D/manufacturing complex

8 years ago

FDA faults IQVIA for errors in opioid sales data, calls for quality review

8 years ago

FDA approves first non-opioid to treat withdrawal symptoms in adults

8 years ago

Will Shire's top R&D talent bolt now that Takeda has struck a merger agreement?

8 years ago

FDA executes an abrupt about-face as sole-source contract for ex-agency chief Mark McClellan draws the spotlight

8 years ago

Citing significant progress on a cure for diabetes, Novo Nordisk beefs up its stem cell pipeline with new ...

8 years ago

The top winners and losers on ASCO abstract night: Loxo, Blueprint, Jounce, Merck KGaA and more

8 years ago

Vectalys and FlashCell merge into Flash Therapeutics, loaded with RNA pipeline and manufacturing set-up

8 years ago

AstraZeneca steps up its use of Emulate's 'organ chip' tech; Ansun Biopharma's parainfluenza therapy attracts $85M ...

8 years ago

Tel Aviv VC fund aMoon gets $250M from Credit Suisse, emerges as top player in Israel

8 years ago

FDA stiff arms Evolus' rival to Allergan’s blockbuster Botox, but execs promise a snap response

8 years ago

His way: Greg Verdine is building a new kind of drug, with backing from a different kind of investor

8 years ago

EIP Pharma flies into a high-risk PhIIb Alzheimer’s study fueled with $20.5M from billionaire Len Blavatnik’s ...

8 years ago

Novartis sacrifices its top attorney in an attempt to quell clamor over $1.2M in Cohen payments — while ex-CEO ...

8 years ago

Seattle's Nohla closes $45M to bring novel stem cell treatment for leukemia to late-stage trials

8 years ago

Pfizer finally finishes a 3-year regulatory odyssey, bagging an FDA OK for 1st Epogen knockoff

8 years ago

Daiichi Sankyo adds $484M pact to its ongoing Zymeworks collaboration; Surface spins out of Imprimis with $20M raise

8 years ago

First page Previous page 1035 1036 103710381039 1040 1041 Next page Last page